Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)
November 14, 2024 16:30 ET
|
Knight Therapeutics
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved...
Knight Therapeutics Reports Third Quarter 2024
November 07, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call
October 31, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
October 15, 2024 08:30 ET
|
Knight Therapeutics
MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate,...
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
September 27, 2024 10:22 ET
|
Knight Therapeutics
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...
Knight Therapeutics Reports Second Quarter 2024
August 08, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported...
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call
August 01, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...
Knight Announces Normal Course Issuer Bid
July 11, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-US) specialty pharmaceutical company, announced today...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
May 09, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...
Knight Therapeutics Reports First Quarter 2024 Results
May 09, 2024 07:30 ET
|
Knight Therapeutics
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial...